Studies on the correlation among the fucosylation index, concentration of α-fetoprotein and des-γ-carboxy prothrombin as prognostic indicators in hepatocellular carcinoma

Hepatology Research

Volumn 27, Issue 4, 2003, Pages 280-288

  Igarashi, Hirotaka ^a   Aoyagi, Yutaka ^a   Suda, Takeshi ^a   Mita, Yuhsaku ^a   Kawai, Kohichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Des carboxy prothrombin; Fucosylation index; Hepatocellular carcinoma; Prognostic factor; Survival rate; Fetoprotein

Indexed keywords

AGGLUTININ; ALCOHOL; ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD CLOTTING; BLOOD LEVEL; CHEMOEMBOLIZATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DISEASE MARKER; FEMALE; FUCOSYLATION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOELECTROPHORESIS; INTERMETHOD COMPARISON; LENTIL; LIVER CELL CARCINOMA; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; MICROWAVE THERAPY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0347525816     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(03)00266-3     Document Type: Article

References (35)

1. Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res 1968;28:1344-50.
2. O'Conor GI, Tatarinov YS, Abelev GI, Uriel J. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 1970;25:1091-8.
3. Liebman H, Furie BC, Tong MJ, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
4. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-γ-carboxy prothrombin) by hepatocellular carcinoma. J Hepatol 1987;4:357-63.
5. Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988;61:1621-8.
6. Hattori N, Ohmizo R, Unoura M, Tanaka N, Kobayashi K. The PIVKA-II collaborative working group. J Tumor Marker Oncol 1988;3:207-16.
7. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. Usefulness of sensitive determination of des-γ-carboxy prothrombin in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998;82:1643-8.
8. Okuda H, Nakanishi T, Takatsu K, et al. Measurement of serum levels of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1998;82:1643-8.
9. Aoyagi Y, Suzuki Y, Isemura M, et al. Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gann 1984;75:809-15.
10. Aoyagi Y, Suzuki Y, Isemura M, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988;61:769-74.
11. Aoyagi Y. Carbohydrate-based measurement on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconj J 1995;12:194-9.
12. Breborowicz J, Mackiewicz A, Breborowicz D. Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affinoelectrophoresis. Scand J Immunol 1981;14:15-20.
13. Taketa K, Sekiya C, Namiki M, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990;99:508-18.
14. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-23.
15. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995;22:802-7.
16. Aoyagi Y, Isemura M, Yosizawa Z, et al. Fucosylation of serum alpha-fetoprotein with primary hepatocellular carcinoma. Biochim Biophys Acta 1985;830:217-23.
17. Aoyagi Y, Suzuki Y, Igarashi K, et al. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer 1993;67:486-92.
18. Taketa K, Ichikawa E, Taga H, Hirai H. Antibody-affinity blotting, a sensitive technique for the detection of alpha-fetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis 1985;6:492-7.
19. Nagasue N, Inokuchi K, Kobayashi M, Saku M. Serum alpha-fetoprotein levels after hepatic artery ligation and postoperative chemotherapy: correlation with clinical status in patients with hepatocellular carcinoma. Cancer 1977;40:615-8.
20. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989;64:1700-7.
21. Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst 1980;64:1329-32.
22. Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991;6:385-91.
23. Izumi R, Shimizu K, Kiriyama M, et al. Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J Surg Oncol 1992;49:151-5.
24. Shimada M, Takenaka K, Fujiwara Y, et al. Des-γ-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996;78:2094-100.
25. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by Vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Cancer 1994;73:2464-71.
26. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol 1995;7:627-33.
27. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996;111:996-1001.
28. Hayashi K, Kumada T, Nakano S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999;94:3028-33.
29. Okuda K, Tanaka M, Kanazawa N, et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by Lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 1999;14:265-71.
30. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H. Fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma. Cancer 1998;83:2076-82.
31. Aoyagi Y, Mita Y, Suda T, et al. The fucosylation index of serum α-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res 2002;23:287-95.
32. Sobin LH, Witterkind C, editors. UICC TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997.
33. Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990;5:616-26.
34. Ichida T, Kato M, Hayakawa A, et al. Therapeutic effect of a CDDP-epirubicin-Lipiodol emulsion on advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(Suppl):S74-8.
35. Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Deletion of serum lectin-reactive α-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 1997;3:727-31.